Cannabit-Tikun Partners with Teva Israel Olam on International Distribution Deal 

大麻-蒂昆与Teva Israel Olam合作国际分销协议

2021-12-29 00:30:08 Ganjapreneur

本文共709个字,阅读需2分钟

Medical cannabis company Cannabit-Tikun is partnering with pharmaceutical firm Teva Israel Olam to produce cannabis products that will be distributed in Israel, Palestine, and eventually Ukraine. Teva said the products will be produced according to the company’s “instructions and stringent standards” under the 10-year collaboration. Yossi Ofek, CEO of Teva, said Israel’s medical cannabis market is “developing and being professionalized at a dizzying pace” and “there is more openness to it in Israel and worldwide.” “Today, it is clear to many in the pharmaceutical industry and in the medical community that use of oils produced from specific cannabis strains may provide additional treatment options and respond to unmet medical needs of patients.” — Ofek in a press release   Cannabit-Tikun Olam General Manager Avinoam Sapir has previously served as Teva Israel CEO from 2013 and later as cluster head for Africa, the Middle East, and Ukraine, through 2020. “I believe that this is one of the most important agreements concluded in the industry in recent years in Israel and that it will position Cannbit-Tikun Olam and Teva Israel as leading players in the ever-growing and developing medical cannabis market in Israel and beyond,” he said in a statement. The oils produced as part of the collaboration are based on strains developed by Cannbit-Tikun Olam and selected by Teva due to their safety profile and strong therapeutic efficacy, the companies said. The deal includes a provision allowing a 9-year extension to the partnership. Earlier this year, Tikun Olam announced a partnership with Ambrosia-SupHerb to produce and market nutritional supplements based on cannabis and mushrooms. Get daily news insights in your inbox. Subscribe End Authored By: TG joined Ganjapreneur in 2014 as a news writer and began hosting the Ganjapreneur podcast in 2016. He is based in upstate New York, where he also teaches media studies at a local university.
医用大麻公司Cannabit-Tikun正与制药公司Teva Israel Olam合作,生产大麻产品,这些产品将在以色列、巴勒斯坦,最终在乌克兰销售。Teva表示,在10年的合作中,这些产品将根据该公司的“指示和严格标准”生产。 Teva首席执行官约西·奥费克(Yossi Ofek)表示,以色列的医用大麻市场“正在以令人眩晕的速度发展和专业化”,“以色列和世界各地对其更加开放”。 “今天,制药业和医学界的许多人都很清楚,使用特定大麻菌株生产的油可能会提供额外的治疗选择,并应对病人未满足的医疗需求。”-Ofek在新闻稿中说 大麻-Tikun Olam总经理Avinoam Sapir此前曾从2013年起担任Teva以色列首席执行官,后来在2020年前担任非洲、中东和乌克兰的集群负责人。 他在一份声明中说:“我相信这是以色列近年来在该行业达成的最重要的协议之一,它将使Cannbit-Tikun Olam和Teva Israel成为以色列及其他地区不断增长和发展的医用大麻市场的主导者。” 两家公司表示,作为合作的一部分生产的油是基于Cannbit-Tikun Olam开发的菌株,Teva因其安全性和强大的治疗效果而选择的。 该协议包括一项允许将合作伙伴关系延长9年的条款。 今年早些时候,Tikun Olam宣布与Ambrosia-SupHerb合作,生产和销售基于大麻和蘑菇的营养补充剂。 在收件箱中获取每日新闻见解。订阅 结束 作者: TG于2014年加入Ganjapreneur担任新闻作家,并于2016年开始主持Ganjapreneur播客。他住在纽约州北部,在当地的一所大学教授媒体研究。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文